Trial · NCT01708603
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Static Physician Global Assessment (sPGA) Score Success (Score of 0 or 1) at Week 12 | 210 mg Brodalumab | 481 | Participants | ||
| Percentage of Participants With Static Physician Global Assessment (sPGA) Score Success (Score of 0 or 1) at Week 12 | 140 mg Brodalumab | 354 | Participants | ||
| Percentage of Participants With Static Physician Global Assessment (sPGA) Score Success (Score of 0 or 1) at Week 12 | Placebo | 12 | Participants | ||
| Percentage of Participants With Static Physician Global Assessment (sPGA) Score Success (Score of 0 or 1) at Week 12 | Ustekinumab | 183 | Participants | ||
| Percentage of Participants With Psoriasis Area Severity Index (PASI) 75 at Week 12 | 210 mg Brodalumab | 528 | Participants | ||
| Percentage of Participants With Psoriasis Area Severity Index (PASI) 75 at Week 12 | 140 mg Brodalumab | 406 | Participants | ||
| Percentage of Participants With Psoriasis Area Severity Index (PASI) 75 at Week 12 | Placebo | 25 | Participants | ||
| Percentage of Participants With Psoriasis Area Severity Index (PASI) 75 at Week 12 | Ustekinumab | 210 | Participants | ||
| Percentage of Participants With Psoriasis Area Severity Index (PASI) 100 at Week 12 | Brodalumab 210mg | 272 | Participants | ||
| Percentage of Participants With Psoriasis Area Severity Index (PASI) 100 at Week 12 | Brodalumab 140mg | 157 | Participants | ||
| Percentage of Participants With Psoriasis Area Severity Index (PASI) 100 at Week 12 | Placebo | 2 | Participants | ||
| Percentage of Participants With Psoriasis Area Severity Index (PASI) 100 at Week 12 | Ustekinumab | 65 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01708603/results